Evaluation of the Psychosocial Impact of the MiniMed Variable-Rate Implantable Insulin Pump

Barrett, D H; Davidson, Paul C.; Steed, Leigh; Ábel, György; Loman, Kimberly; Saudek, C. D.

doi:10.1097/00007611-199512000-00008

Cited by 9 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite these drawbacks, there has been an increasing amount of data gathered on the implantable pump over the 15 years and more since it was first developed69, 70. There was a worldwide experience in excess of 600 patients who have received insulin delivered into the peritoneal space with IIP as of 199671.…”

Section: The Implantable Insulin Pumpmentioning

confidence: 99%

Insulin pump therapy in Type 1 pediatric patients: now and into the year 2000

Kaufman

Halvorson

Miller

et al. 1999

Diabetes Metab. Res. Rev.

View full text Add to dashboard Cite

There are a number of medical conditions such as growth failure in children, pregnancy, lipid abnormalities, and early complications that are improved by the meticulous glycemic control that can be achieved with insulin pump therapy (CSII). By using an insulin pump, many patients with severe hypoglycemia, the dawn phenomenon, extremes of glycemic excursion, recurrent diabetic ketoacidosis (DKA) and hypoglycemia unawareness have amelioration of these problems. However, pump therapy involves problems such as weight gain, recurrent ketosis due to pump failure, infections, and risk of hypoglycemia. Owing to many developmental issues, young children may not be able to wear the pump without parental supervision. We have used the pump at night time only in these patients. This has allowed children of 7–10 years of age to benefit from improved nocturnal glycemia without the risk of pump therapy when they are without an adult to help. We have also used the pump in subjects with recurrent DKA and in our general patient population (mean age 13.6±3.9 years). In our pump cohort, CSII led to improvement in quality of life, knowledge, adherence, and responsibility. A reduction in hypoglycemia, DKA rate and mean HbA1c was associated with pump usage. For this to occur, however, pump education must be geared to the pediatric subject and his/her family. Education materials and tools help in learning how to use the pump and how to deal with the intricacies of basal and bolus dosing, and the effect of exercise, food and illness on diabetes management. The pump has improved since it was first introduced and these modifications have made it easier, more painless and less hazardous. With the development of continuous glucose sensors and implantable pumps, the next century will see pump therapy lead to the artificial pancreas. Copyright © 1999 John Wiley & Sons, Ltd.

show abstract

Section: The Implantable Insulin Pumpmentioning

confidence: 99%

Insulin pump therapy in Type 1 pediatric patients: now and into the year 2000

Kaufman

Halvorson

Miller

et al. 1999

Diabetes Metab. Res. Rev.

View full text Add to dashboard Cite

show abstract

“…Patients using implantable pump did not differ from control subjects on any measure of psychosocial function but that pump users monitored their blood glucose levels more frequently and had lower average blood glucose levels [40].…”

Section: Micropumpsmentioning

confidence: 78%

An Integrated Platform for Bio-Analysis and Drug Delivery

Amer¹,

Badawy

2005

CPB

View full text Add to dashboard Cite

The advances in the microelectronics fabrication allow the strong appearance of micro-electro-mechanical systems known as MEMS. MEMS enable the fabrication of smaller devices that are manufactured using standard micro-fabrication techniques similar to the ones that are used to create computer silicon chips. Several MEMS devices including micro-reservoirs, micro-pumps, cantilevers, rotors, channels, valves, sensors, and other structures have been designed, fabricated and tested from using materials that have been demonstrated to be biocompatible. This paper reviews the status of Micro-electronic and MEMS systems that can be used for adaptive drug administration. It presents different components and describes a possible implementation. Finally it presents a prototype that is termed ipill which stands intelligent pill.

show abstract

“…One study found that patients with the implantable pump did not differ from control subjects on any measure of pshycosocial function but that pump users monitored their blood glucose levels more frequently and had lower average blood glucose levels [44]. Even though this type of device may improve patient's mobility and reduce infections by eliminating transcutaneous catheters, they may still be hampered by their size, cost, ability to deliver only drugs in solution, and the limited stability of some drugs in solution at 37°C.…”

Section: Electro-responsive Pulsatile/ Triggered Releasementioning

confidence: 99%

Stimuli-induced Pulsatile or Triggered Release Delivery Systems for Bioactive Compounds

Anal¹

2007

EMI

View full text Add to dashboard Cite

As is frequently found in the living body, many vital functions are regulated by pulsed or triggered release of bioactive substances at a specific site and time. Thus it is important to develop new drug delivery devices to achieve pulsed delivery of a certain amount of drugs in order to mimic the function of the living systems to minimize the undesired side effects. The pulsed or triggered delivery systems are designed to alter their rate of drug delivery in response to stimuli such as changes in a specific molecule, a magnetic or electric field, temperature, light or mechanical forces. Such systems are suitable for the release of therapeutics that benefit from non-constant plasma concentrations. In this article, several types of drug delivery systems which cause the pulsed or triggered release of bioactive compounds due to certain external stimuli, mostly focuses on thermally-, electrically-and magnetically-induced release are described in detail. The recent patents on various delivery systems which release the active compounds only with the external stimuli are described in detail.

show abstract

Evaluation of the Psychosocial Impact of the MiniMed Variable-Rate Implantable Insulin Pump

Cited by 9 publications

References 0 publications

Insulin pump therapy in Type 1 pediatric patients: now and into the year 2000

Insulin pump therapy in Type 1 pediatric patients: now and into the year 2000

An Integrated Platform for Bio-Analysis and Drug Delivery

Stimuli-induced Pulsatile or Triggered Release Delivery Systems for Bioactive Compounds

Contact Info

Product

Resources

About